Unmet need & competitive intelligence

• Unmet needHow patients are treated now, where outcomes remain poor, and which gaps matter to treating physicians and to regulators.
• Trial and treatment landscapeOngoing and reported trials organized by setting, line of therapy, biomarker and mechanism rather than by company, so that overlap and white space are visible.
• Readout interpretationWhat a new result shows once population, design, follow-up and endpoints are taken into account, and what a cross-trial comparison can and cannot support.
• Implications for your programThe effect on your comparator, eligibility, endpoints, enrollment and positioning, with the options and the evidence that would distinguish them.

Standards of care move quickly. A single approval or readout can change the control arm, make a population harder to enroll or raise the bar for differentiation. Small teams rarely have a dedicated intelligence function, and a feed of press releases does not say whether the plan should change.

The value lies in clinical interpretation: who was enrolled, how mature the data are, what the comparator is in practice, and whether a result transfers to your setting.

• A competitor reads out,or a treatment is approved in your setting.
• You are choosingbetween indications or combination strategies.
• A board, partnering or investor discussionneeds a current and defensible landscape.
• You are defining the comparatoror standard of care for a protocol.

1. Frame the question The decision, the audience and the time available.
2. Gather and verify sources Peer-reviewed publications, regulatory documents, congress material and company disclosures, with the limits of each noted.
3. Interpret in context Separate what was reported from what is inferred, and test the result against your population and endpoints.
4. Brief A concise, decision-oriented document with recommended actions and what to watch next.

• A sourced clinical decision brief
• A focused landscape of competing programs and standards of care in your setting
• An implications matrix linking developments to possible actions
• Optional event-triggered or scheduled updates

• StructureOne brief, a milestone update, or an agreed recurring service. The scope is deliberately narrow enough to stay useful.
• What we need from youThe indication, mechanism or asset context, the decision to inform, and any source-access constraints.
• Roles and limitsThis is clinical interpretation, not a proprietary database or a real-time monitoring service. Cross-trial comparisons are treated cautiously and source limitations stay visible.